Regulus Therapeutics Inc [RGLS] stock is trading at $2.36, up 71.01%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The RGLS shares have gain 59.46% over the last week, with a monthly amount glided 51.28%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 12, March 2024, Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity. In a post published today on Yahoo Finance, Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the “Company” or “Regulus”), today announced that it has entered into a definitive securities purchase agreement in connection with a private placement to certain institutional investors and other accredited investors. The oversubscribed financing includes participation from new and existing institutional investors, including Adage Capital Partners L.P., Deep Track Capital, the Federated Hermes Kaufmann Funds, New Enterprise Associates (NEA), Octagon Capital, RA Capital Management, and Vivo Capital. Upon the closing of the financing, which is anticipated to occur on or about March 14, 2024, the Company expects to receive gross proceeds of approximately $100 million. The closing of the financing is subject to customary closing conditions.
From an analyst’s perspective:
Regulus Therapeutics Inc [NASDAQ: RGLS] stock has seen the most recent analyst activity on March 28, 2018, when B. Riley FBR Inc. initiated its Neutral rating and assigned the stock a price target of $1. Previously, Leerink Partners started tracking the stock with Outperform rating on January 05, 2018, and set its price target to $2. On June 13, 2017, Chardan Capital Markets reiterated its Buy rating and revised its price target to $2.50 on the stock. Wedbush reiterated its Outperform rating and decreased its price target to $6 on March 06, 2017. Wells Fargo downgraded its rating to a Market Perform. Needham downgraded its rating to Hold for this stock on January 30, 2017. In a note dated December 07, 2016, Chardan Capital Markets reiterated an Buy rating on this stock and revised its target price from $12 to $5.
Regulus Therapeutics Inc [RGLS] stock has fluctuated between $0.76 and $2.14 over the past year. Regulus Therapeutics Inc [NASDAQ: RGLS] shares were valued at $2.36 at the most recent close of the market.
Analyzing the RGLS fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.76, Equity is -0.94 and Total Capital is -1.01. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.12.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.6300 points at the first support level, and at 0.9000 for the second support level. However, for the 1st resistance point, the stock is sitting at 3.4400, and for the 2nd resistance point, it is at 4.5200.
Regulus Therapeutics Inc [RGLS] reported earnings per share of -$0.4 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.4/share, meaning a difference of $0 and a surprise factor of 0.00%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were -$0.37 per share as compared to estimates of -$0.41 per share, a difference of $0.04 representing a surprise of 9.80%.
Ratios To Look Out For
For context, Regulus Therapeutics Inc’s Current Ratio is 3.89. Also, the Quick Ratio is 3.89, while the Cash Ratio stands at 3.13.
Transactions by insiders
Recent insider trading involved Hagan Joseph P, Chief Executive Officer, that happened on Jan 18 ’24 when 14580.0 shares were sold. Chief Financial Officer, CALSADA CRISPINA completed a deal on Jan 18 ’24 to sell 5468.0 shares. Meanwhile, Sr. VP & General Counsel Aker Christopher Ray sold 5468.0 shares on Jan 18 ’24.
